12th Annual Updates from ASH 2026: Practice Changing Abstracts

Elevate Your Impact in Hematologic Oncology!

Join us for an event that unites community-based providers and academic oncologists, all dedicated to enhancing the care and outcomes of patients with hematologic malignancies. This activity will explore the latest treatment options and medical advancements aimed at reducing cancer-related deaths. You’ll gain insights into groundbreaking therapies like CAR T-cell therapy, novel immunotherapies, and targeted agents that represent the forefront of managing both newly diagnosed and relapsed blood cancers.

Stay informed with the latest scientific updates and innovative strategies that directly impact your practice. Participants will engage in discussions about rapidly evolving treatment landscapes, evaluate critical considerations for sequencing novel agents, and refine practice paradigms that elevate patient care across all treatment settings.

This is your chance to enhance your knowledge of best practices for treating hematologic cancers while learning when to refer patients for specialized quaternary care and clinical trial opportunities. Don’t miss out on this chance to stay ahead in your field—register today to secure your spot and transform your approach to patient management!

Target Audience
This conference is designed for hematologists, medical oncologists, pathologists, fellow and resident trainees, nurse practitioners, physician assistants, nurses, pharmacists, and all healthcare professionals dedicated to the treatment of hematologic cancers.

Learning Objectives
· Illustrate how new data presented at the 2026 Annual Meeting of the American Society of Hematology can apply to clinical practice;

· Discuss emerging novel treatment strategies, the role of targeted agents in therapeutic paradigms for patients with lymphoid malignancies, and available clinical trial options and other approaches for patients with relapsed/refractory disease;

· Discuss optimal patient selection, timing, and regimens for stem cell transplantation with high-risk and relapsed/refractory disease;

· Interpret emerging clinical trial data in the context of cellular therapies for hematologic malignancies and its place in evolving hematologic malignancy treatment standards;

· Evaluate available treatments for the care of patients with lymphoma based on optimal treatment sequencing, novel agents and their role in earlier lines of therapy, and how these change best practices for evidence-based care of both newly diagnosed and relapsed/refractory cases; 

· Discuss evolving treatment paradigms and therapy sequencing for novel agents in the care of patients with multiple myeloma, including approved and emerging CAR T-cell therapies, bispecific antibodies targeting BCMA and GPRC5D, and dual-antigen targeting strategies; 

· Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common classic hematologic disorders, including newly approved therapeutic classes such as menin inhibitors and next-generation BCL-2 inhibitors;

· Discuss international trends in the care of hematologic malignancies.

Accreditation Statements

This event is pending accreditation, please check back for more information.